<sup>64</sup>Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
2013 · Journal of Nuclear Medicine · 287 citations
https://doi.org/10.2967/jnumed.112.118612
M
Mayu Yunokawa
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
269
Papers
6.0K
Citations
34
h-index
82
i10-index
Mayu Yunokawa is an academic researcher from Cancer Institute (WIA). The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & Endometrial and Cervical Cancer Treatments & Sarcoma Diagnosis and Treatment. The author has an h-index of 34, co-authored 229 publications.
ORCID: 0000-0001-7354-6977Papers by this author
worksPathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
2019 · Gynecologic Oncology · 117 citations
https://doi.org/10.1016/j.ygyno.2019.04.679
Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2
2008 · Oncogene · 95 citations
https://doi.org/10.1038/onc.2008.58
Efficacy of everolimus, a novel m<scp>TOR</scp> inhibitor, against basal‐like triple‐negative breast cancer cells
2012 · Cancer Science · 95 citations
https://doi.org/10.1111/j.1349-7006.2012.02359.x
Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer
2014 · Annals of Oncology · 59 citations
https://doi.org/10.1093/annonc/mdu247
TERT promoter hotspot mutations in breast cancer
2017 · Breast Cancer · 37 citations
https://doi.org/10.1007/s12282-017-0825-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat